Pomalidomide in Multiple Myeloma: Mechanism, Clinical Use, and Safety Profile

Pomalidomide in Multiple Myeloma is an oral immunomodulatory drug (IMiD) used to treat relapsed and refractory multiple myeloma. As a third-generation IMiD, it binds to cereblon, triggering degradation of transcription factors IKZF1 and IKZF3, resulting in direct anti-myeloma effects and enhanced immune-mediated tumor cell killing. Often combined with dexamethasone and monoclonal antibodies such as daratumumab, pomalidomide demonstrates efficacy in lenalidomide- and proteasome inhibitor–refractory disease. Its safety profile includes hematologic toxicities, infection risk, venous thromboembolism, and teratogenicity, managed via monitoring and the REMS program. Pomalidomide remains a critical agent in modern multiple myeloma therapy, offering improved outcomes for heavily pretreated patients.

What Is Pomalidomide?

Pomalidomide is an oral immunomodulatory drug (IMiD) primarily used in the treatment of relapsed and refractory multiple myeloma (RRMM). It is a third-generation IMiD, following thalidomide and lenalidomide, and was developed to address disease progression in patients who no longer respond adequately to earlier therapies. Pomalidomide is marketed under the brand names Pomalyst® in the United States and Imnovid® in Europe and other regions.

Structurally and pharmacologically related to thalidomide, pomalidomide was designed to retain strong anti-myeloma efficacy while offering improved immunologic activity. Compared with lenalidomide, pomalidomide demonstrates greater potency at lower doses, particularly in myeloma cells that have become resistant to prior IMiD therapy. This enhanced activity has positioned pomalidomide as a critical option in later lines of treatment.

From a therapeutic standpoint, pomalidomide exerts anti-cancer, immunostimulatory, and anti-angiogenic effects. It is most commonly administered in combination with low-dose dexamethasone, and modern treatment regimens frequently pair it with monoclonal antibodies such as daratumumab or isatuximab to further improve clinical outcomes. These combination strategies have significantly extended progression-free survival in heavily pretreated patients.

Like other IMiDs, pomalidomide carries a well-defined safety framework. It is highly teratogenic, requiring strict pregnancy prevention measures and regulatory oversight programs such as the FDA’s REMS system. Despite these restrictions, its clinical benefits in difficult-to-treat multiple myeloma populations are well established.

Overall, pomalidomide represents a key advancement in myeloma therapy, filling an important unmet need for patients with disease refractory to earlier-generation treatments and continuing to play a central role in evolving combination regimens.

Mechanism of Action of Pomalidomide

Pomalidomide exerts its antitumor activity through a cereblon (CRBN)-dependent mechanism, which is central to the pharmacology of all immunomodulatory drugs (IMiDs). Cereblon is a substrate receptor of the CRL4 E3 ubiquitin ligase complex. Upon binding to cereblon, pomalidomide alters the substrate specificity of this complex, leading to the ubiquitination and subsequent proteasomal degradation of key transcription factors, most notably IKZF1 (Ikaros) and IKZF3 (Aiolos).

The degradation of IKZF1 and IKZF3 has direct and indirect antimyeloma effects. In multiple myeloma cells, loss of these transcription factors results in reduced expression of survival proteins such as IRF4 and MYC, which are critical for plasma cell growth and proliferation. This ultimately leads to growth arrest and apoptosis of malignant myeloma cells. Compared with lenalidomide, pomalidomide shows greater potency in inducing cereblon-mediated protein degradation, which explains its activity in lenalidomide-refractory disease.

In addition to its direct cytotoxic effects, pomalidomide has pronounced immunomodulatory properties. It enhances T-cell activation by increasing interleukin-2 (IL-2) production and co-stimulatory signaling, while simultaneously augmenting natural killer (NK) cell–mediated cytotoxicity. These immune effects improve recognition and elimination of myeloma cells, particularly when pomalidomide is combined with monoclonal antibodies that rely on antibody-dependent cellular cytotoxicity (ADCC).

Pomalidomide also exhibits anti-angiogenic and anti-inflammatory activity, partly through the suppression of pro-tumor cytokines such as tumor necrosis factor-α (TNF-α) and vascular endothelial growth factor (VEGF). The convergence of direct tumor cell targeting, immune system activation, and microenvironment modulation underpins the clinical efficacy of pomalidomide in advanced multiple myeloma and supports its role as a backbone agent in modern combination regimens.

Clinical Uses and Indications of Pomalidomide

Pomalidomide is primarily indicated for the treatment of relapsed and refractory multiple myeloma (RRMM), particularly in patients who have received multiple prior lines of therapy. Regulatory approvals specify its use in patients who have been previously treated with lenalidomide and a proteasome inhibitor, and whose disease has demonstrated progression during or shortly after these therapies. This positioning reflects pomalidomide’s ability to overcome resistance to earlier-generation immunomodulatory drugs.

The most established and widely used regimen is pomalidomide in combination with low-dose dexamethasone (Pd). This doublet demonstrated significant improvements in progression-free survival and overall response rates compared with high-dose dexamethasone alone in heavily pretreated populations. As treatment strategies have evolved, pomalidomide has increasingly been incorporated into triplet and quadruplet regimens to enhance depth and durability of response.

Notably, pomalidomide serves as a backbone agent in combination with anti-CD38 monoclonal antibodies, such as daratumumab and isatuximab. Clinical trials including APOLLO and ICARIA-MM have shown that adding these antibodies to pomalidomide and dexamethasone significantly improves progression-free survival and overall response rates compared with Pd alone. These combinations are now widely adopted in clinical practice for patients with advanced disease.

Beyond antibody-based regimens, pomalidomide has also been evaluated in combination with proteasome inhibitors and other novel agents, supporting its flexibility across multiple therapeutic strategies. Its oral administration and predictable pharmacokinetic profile further enhance its practicality in long-term disease management.

Overall, pomalidomide plays a critical role in the modern treatment landscape of multiple myeloma. Its proven efficacy in refractory disease, compatibility with diverse combination partners, and central role in guideline-recommended regimens make it an essential option for patients with limited remaining therapeutic alternatives.

Safety Profile and Side Effects of Pomalidomide

Pomalidomide is generally well-tolerated in patients with relapsed or refractory multiple myeloma, but it is associated with a defined spectrum of adverse events that require careful monitoring. The most common side effects are hematologic, including neutropenia, anemia, and thrombocytopenia. These effects are dose-dependent and may necessitate dose reductions or temporary treatment interruptions. Clinicians frequently monitor blood counts on a regular schedule to manage these toxicities proactively.

In addition to hematologic effects, pomalidomide can cause fatigue, gastrointestinal disturbances (nausea, diarrhea, constipation), and rash. Infection risk is elevated due to immunosuppression, particularly when neutropenia is present. Patients are often advised to receive prophylactic antibiotics or antiviral agents in specific clinical scenarios to mitigate infectious complications.

A significant concern with pomalidomide, as with all immunomodulatory drugs, is teratogenicity. The drug can cause severe birth defects, and strict pregnancy prevention measures are mandated under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. Both male and female patients of reproductive potential must adhere to contraceptive requirements during therapy and for a period after discontinuation.

Another serious but less frequent risk is venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. The risk increases when pomalidomide is combined with dexamethasone or other agents that predispose to clotting. Prophylactic anticoagulation is recommended for patients with additional risk factors.

Overall, while pomalidomide carries predictable risks, its adverse effects can generally be managed effectively with monitoring, dose adjustments, and supportive care, allowing patients to benefit from its potent anti-myeloma activity.

Conclusion

Pomalidomide is a potent immunomodulatory drug that has transformed the management of relapsed and refractory multiple myeloma. By targeting the cereblon pathway, it induces degradation of key transcription factors, leading to direct anti-myeloma effects while simultaneously enhancing T-cell and NK-cell immune activity. Its oral administration, efficacy in lenalidomide-refractory disease, and compatibility with combination therapies—particularly with dexamethasone and anti-CD38 antibodies—make it a cornerstone in modern myeloma treatment. While associated with predictable hematologic and non-hematologic adverse effects, careful monitoring and adherence to safety programs, including REMS, allow patients to maximize therapeutic benefit. Overall, pomalidomide exemplifies the advances in targeted, immunomodulatory therapy, offering hope and improved outcomes for patients with advanced myeloma.